BostonGene
BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.
- Company typePrivate
- Founded2015
- HeadquartersWaltham, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingSoftware
What BostonGene does
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies
BostonGene firmographics
Firmographics- Name
- BostonGene
- Legal name
- BostonGene Corporation
- Website
- http://www.bostongene.com/
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.
- Ownership category
- akta.pro rank
BostonGene industry classification
Industry- Product category
- Precision Oncology Analytics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where BostonGene is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BostonGene business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Biopharma Partnerships and Platform Services: BostonGene generates revenue through strategic partnerships with biopharmaceutical organizations, providing AI-powered analytics platforms for drug development, patient selection, and clinical trial optimization. Engagements typically begin as focused pilots and expand into broader platform integration.
- Clinical Laboratory Testing Services: BostonGene operates through its CLIA-certified, CAP-accredited laboratory providing molecular profiling services including whole exome sequencing, transcriptome sequencing, liquid biopsy, and immunoprofiling for healthcare providers and biopharma partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise biopharma partnerships with AI-powered analytics platform access |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
BostonGene product offering
Product offeringCore offering
BostonGene provides a cloud-based AI-driven multimodal analytics platform that integrates whole exome sequencing, whole transcriptome sequencing, liquid biopsy, immune profiling, spatial proteomics, and digital pathology to analyze tumors, microenvironments, and host immunity. The company sells its BostonGene Tumor Portrait® test and related clinical assays to healthcare providers and oncologists, and offers AI-powered target identification, biomarker discovery, clinical trial support, and drug repurposing modules to biopharmaceutical partners via a subscription/enterprise model.
Product overview
BostonGene offers a cloud-based AI platform that integrates multiple molecular and immune profiling techniques to comprehensively analyze tumors, microenvironments, and host immunity for precision oncology. The platform combines whole exome sequencing, whole transcriptome sequencing, liquid biopsy (ctDNA/cfRNA), single-cell RNA sequencing, flow cytometry, spatial proteomics, and digital pathology into a unified system. For biopharma clients, the platform provides target identification, biomarker discovery, clinical trial support, drug repurposing, and unmet need identification modules. For healthcare providers, BostonGene offers the BostonGene Tumor Portrait test, Immune System Profiling, IHC testing, and Unknown Primary testing. The company operates its own CLIA-certified, CAP-accredited laboratory and partners with leading biopharmaceutical organizations and academic institutions.
Differentiator
Problem solved
Functional benefit
Brands
- Kassandra™: AI-based tool that reconstructs tumor microenvironment from gene expression data
- BostonGene Tumor Portrait® test
- PAM50(BG)
Products and services
- BostonGene Tumor Portrait® test Integrated solution providing a holistic 360° overview for each cancer patient, identifying key biomarkers for response to various therapies in patients with advanced solid tumors. Uses DNA whole exome and RNA transcriptome sequencing for comprehensive molecular profiling.
- Immune System Profiling Blood-based immune profiling providing a snapshot of the patient's immune health by identification of hundreds of different cell types from a single tube of blood, using flow cytometry and AI-based models.
- Immunohistochemistry (IHC) test AI-based testing for clinically actionable biomarkers such as PD-L1 and MMR with automated workflow applicable to various markers including nuclear, cytoplasm/membrane, and complex membrane markers.
- Unknown Primary test Identifies the tumor's origin using DNA and RNA sequencing to help guide treatment decisions for patients with cancers of unknown primary.
- Whole Transcriptome Sequencing (WTS / RNA-seq) Sequencing of nearly 20,000 genes enabling precise identification of gene fusions, expression levels, and gene expression signatures in a CLIA/CAP environment, with tumor microenvironment analysis, TCR/BCR repertoire, and HLA haplotyping.
- Whole Exome Sequencing (WES) Sequencing of nearly 20,000 genes providing uniform coverage across 99.7% of coding regions, enabling unbiased detection of genetic variants (SNVs, indels, CNAs, LOH, TMB, MSI) in a CLIA/CAP environment.
- Liquid Biopsy (ctDNA and cfRNA sequencing) Minimally invasive blood-based tumor profiling enabling identification of biomarkers and monitoring of treatment response at both DNA and RNA levels via ctDNA and cfRNA assays.
- Single-cell RNA sequencing High-resolution analysis of individual transcriptomes from thousands of cells within a single sample, revealing cell-specific transcriptional changes and identifying rare, functionally significant cell populations.
- Flow Cytometry State-of-the-art flow cytometry including analytical flow cytometry and cell sorting to assess immune system status from standard blood samples. Supports basic immunoprofiling (10 panels, >800 cell populations) and advanced immunoprofiling.
- Spatial Proteomics End-to-end multiplex immunofluorescence (MxIF) pipeline offering comprehensive overview of tissue architecture and cell-cell interactions by detecting up to 60 protein markers from a single slide with single-cell resolution.
- Digital Pathology AI-based digital pathology platform that identifies distinct characteristics of tumor and microenvironment, reducing need for manual analysis. Supports H&E analysis, IHC detection, and multiplex immunofluorescence from whole-slide images.
- Biomarker Discovery Platform AI-powered platform for biomarker discovery and validation, integrating multiomic data including genomics, transcriptomics, and immune profiling to improve patient selection, optimize trial design, and accelerate oncology drug development.
- Target Analysis Solution Leverages proprietary genomic and transcriptomic databases to pinpoint the most promising cancer types for drug candidates and identify novel therapeutic targets.
- Drug Repurposing Solutions AI-driven end-to-end drug repurposing platform discovering beneficial drug-disease matches to maximize the potential of existing drug portfolios.
Quantifiable outcome
- Identified actionable RNA findings in all enrolled patients in FEASY study
- +2 more outcomes
Companies that use BostonGene
Customer profileNamed customers12 records
Segments3 records
Ideal customer profiles2 records
BostonGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability7 records
Feature11 records
BostonGene partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, minor and flagship.
- Kyoto UniversitycoreStrategic research partnership supporting multicenter Phase II clinical trial evaluating combined immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for advanced gastrointestinal cancers. BostonGene applies its multimodal AI analytics platform to identify molecular signatures and immune-response patterns associated with therapeutic response.
- Hokkaido UniversitycoreExpanded multi-year strategic research collaboration to advance precision oncology in Japan. BostonGene conducts next-generation sequencing and integrated analysis of DNA, RNA, and immune profiles from tumor samples across more than 20 cancer types to identify patient-specific disease drivers and guide therapeutic decision-making.
- ImmunoGenesiscoreStrategic partnership to accelerate clinical development of IMGS-001, a cytotoxic immune checkpoint inhibitor targeting both PD-L1 and PD-L2. BostonGene applies its AI-driven multiomic and spatial biology platform to perform molecular characterization and identify patients most likely to respond to treatment.
- UnileverminorStrategic collaboration to apply advanced AI and multiomics approaches to scientific exploration and long-term innovation in consumer products. The partnership extends BostonGene's AI foundation model beyond oncology into consumer-focused science.
- Daiichi SankyoflagshipStrategic collaboration to integrate AI-driven translational intelligence into Daiichi Sankyo's antibody drug conjugate (ADC) development program. BostonGene generates digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles to enable precise patient selection and optimize clinical trial design.
- AstraZenecaflagshipStrategic collaboration to advance oncology drug development using BostonGene's multimodal AI platform. AstraZeneca applies BostonGene's omnimodal analytics to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials, accelerating development timelines and reducing risk across its oncology portfolio.
- TakedacorePartnership to leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials. BostonGene performs sophisticated multiomic analytics including flow cytometry, RNA-seq, and proteomics data to enhance trial design, improve indication selection, and identify biomarker signatures for response and toxicity.
- MD Anderson Cancer CentercoreCollaborative research in FEASY study published in Cancer Discovery demonstrating that RNA-based multiomic analysis identified new therapeutic targets for antibody-drug conjugates in patients with advanced solid tumors who previously had no actionable results from DNA testing alone.
- Memorial Sloan Kettering Cancer CentercoreCollaborative research demonstrating integrated molecular profiling for refining risk assessment, predicting CAR-T therapy resistance, and identifying biomarkers for patient selection in blood cancers. Partnership on multi-omic profiling to identify genomic subtypes associated with differential outcomes after CAR-T therapy.
- Weill Cornell MedicinecoreCollaborative research on AI-driven multiomics platforms for blood cancer treatment optimization including CAR-T therapy outcomes and lymphoma research.
- Friends of Cancer ResearchcoreCollaboration on landmark blinded, multi-vendor HER2 benchmarking study published in Modern Pathology. BostonGene's AI foundation model received independent validation achieving high agreement rates across 10 AI models for assessing HER2 expression in breast cancer.
- UT MD Anderson Cancer CentercoreCollaborative research on integrated transcriptomic and immune profiling for chronic lymphocytic leukemia treatment, pancreatic cancer KRAS/MTAP analysis, and multiple myeloma risk stratification research.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
BostonGene competitors and assessment
Company assessmentDirect peers
- Tempus AI: Tempus AI is the most direct competitor, offering a multimodal AI platform that integrates genomic, transcriptomic, imaging, and clinical data for biopharma R&D and clinical oncology decision support — overlapping with BostonGene across both biopharma partnerships and clinical diagnostics offerings.
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) used widely for therapy selection and biopharma trial enrollment — directly overlapping with BostonGene's Tumor Portrait and biopharma patient stratification offerings.
- Caris Life Sciences: Caris offers MI Profile and Caris Assure for multiomic tumor profiling plus biopharma services including Caris Discovery — directly comparable to BostonGene's combined lab services and biopharma platform strategy in precision oncology.
- Personalis: Personalis provides ImmunoID Next and NeXT Personal liquid biopsy tests and biopharma services for tumor molecular profiling — overlapping with BostonGene's WES/WTS, liquid biopsy, and biopharma analytics offerings.
- PathAI: PathAI builds AI-powered pathology and biomarker platforms deployed with biopharma for clinical trial analytics and companion diagnostics — directly comparable to BostonGene's digital pathology and biopharma AI platform modules.
- Owkin: Owkin operates an AI platform for patient stratification, biomarker discovery, and trial optimization serving biopharma — directly overlapping with BostonGene's biopharma target identification, biomarker discovery, and clinical trial support modules.
- Paige AI: Paige builds AI-based digital pathology models including Paige Prostate (FDA-authorized) for cancer diagnosis and biopharma applications — directly comparable to BostonGene's AI-based digital pathology, IHC detection, and HER2 benchmarking work.
Broad incumbents
- Guardant Health: Guardant Health is a liquid biopsy leader (Guardant360, Reveal) with a broader commercial footprint and FDA-approved diagnostics — overlapping with BostonGene's liquid biopsy (cfDNA/cfRNA) services but with established payer coverage and a public market scale BostonGene does not yet have.
Emerging players
- Natera: Natera's Signatera MRD test and oncology offerings compete in molecular monitoring and treatment response — partial overlap with BostonGene's liquid biopsy and treatment-response monitoring services, primarily in the clinical rather than biopharma channel.
- Recursion Pharmaceuticals: Recursion applies AI foundation models across multiomic and imaging data for drug discovery, with biopharma partnerships — adjacent to BostonGene's biopharma AI platform and foundation-model approach, though Recursion focuses more on therapeutic discovery rather than trial analytics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
BostonGene social profiles
Digital presenceBostonGene compliance and trust
Trust signalCompliance4 records
BostonGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
BostonGene leadership team
Management profileNumber of profiles
Profiles5 records
BostonGene subsidiaries and ownership
Company hierarchySubsidiaries2 records
BostonGene funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BostonGene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BostonGene
What does BostonGene do?
BostonGene provides a cloud-based AI-driven multimodal analytics platform that integrates whole exome sequencing, whole transcriptome sequencing, liquid biopsy, immune profiling, spatial proteomics, and digital pathology to analyze tumors, microenvironments, and host immunity. The company sells its BostonGene Tumor Portrait® test and related clinical assays to healthcare providers and oncologists, and offers AI-powered target identification, biomarker discovery, clinical trial support, and drug repurposing modules to biopharmaceutical partners via a subscription/enterprise model.
Is BostonGene a public or private company?
BostonGene is a private company. It is classified as venture growth investor backed and is currently operating.
When was BostonGene founded?
BostonGene was founded in 2015. It employs 501 to 1,000 people.
Where is BostonGene based?
BostonGene is headquartered in Waltham, United States, in the North America region.
How does BostonGene make money?
Two revenue lines are on record. Biopharma Partnerships and Platform Services are the primary driver. The others are clinical Laboratory Testing Services.
Who are BostonGene's main competitors?
Direct peers on record are Tempus AI, Foundation Medicine, Caris Life Sciences, Personalis, PathAI, Owkin and Paige AI. Guardant Health is listed as a broad incumbent. Emerging players are Natera and Recursion Pharmaceuticals.
Does BostonGene have an API?
No public API is recorded for BostonGene.
What industry is BostonGene in?
BostonGene's product category is Precision Oncology Analytics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 621511 and its SIC code is 2835.